Dynorphin 1-17 (DYN 1-17) is biotransformed rapidly to a range of fragments in rodent inflamed tissue with dynorphin 3-14 (DYN 3-14) being the most stable and prevalent. DYN 1-17 has been shown previously to be involved in the regulation of inflammatory response following tissue injury, in which the biotransformation fragments of DYN 1-17 may possess similar features. This study investigated the effects of DYN 3-14 on lipopolysaccharide (LPS)-induced nuclear factor-kappaB/p65 (NF-B/p65) nuclear translocation and the release of pro-inflammatory cytokines interleukin-1beta (IL-1␤) and tumor necrosis factor-alpha (TNF-␣) in differentiated THP-1 cells. Treatment with DYN 3-14 (10 nM) resulted in 35% inhibition of the LPS-induced nuclear translocation of NF-B/p65. Furthermore, DYN 3-14 modulated both IL-1␤ and TNF-␣ release; inhibiting IL-1␤ and paradoxically augmenting TNF-␣ release in a concentration-independent manner. A number of opioids have been implicated in the modulation of the toll-like receptor 4 (TLR4), highlighting the complexity of their immunomodulatory effects. To determine whether DYN 3-14 modulates TLR4, HEK-Blue TM − hTLR4 cells were stimulated with LPS in the presence of DYN 3-14. DYN 3-14 (10 M) inhibited TLR4 activation in a concentration-dependent fashion by suppressing the LPS signals around 300-fold lower than LPS-RS, a potent TLR4 antagonist. These findings indicate that DYN 3-14 is a potential TLR4 antagonist that alters cellular signaling in response to LPS and cytokine release, implicating a role for biotransformed endogenous opioid peptides in immunomodulation.
Introduction
Innate immune cells such as macrophages are directed immediately to the inflamed site and conferred as the first line of defense against invading pathogens or tissue injury [1] . Recognition of pathogen-associated molecular patterns by pattern-recognition receptors (PRRs) expressed on innate immune cells results in multiple intracellular signalling cascades and release of various inflammatory-related effector molecules [2] . Of the PRRs, toll-like receptor 4 (TLR4) is extensively studied and the best-characterized Abbreviations: DYN, dynorphin; IL-1␤, interleukin-1beta; LPS, lipopolysaccharide; NF-B/p65, nuclear factor-kappaB/p65; PMA, phorbol 12-myristate 13-acetate; TLR4, toll-like receptor 4; TNF-␣, umour necrosis factor-alpha.
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human homologue of the Drosophila toll. TLR4 specifically recognizes bacterial endotoxin lipopolysaccharide (LPS), the major component of the outer membrane of Gram-negative bacteria [3] . The recognition of LPS by TLR4 is facilitated by accessory molecules including myeloid differentiation 2 (MD2) and also CD14 that functions solely as a ligand-binding protein for LPS [4] . Engagement of LPS to MD2/TLR4 complexes triggers the classical nuclear factor-kappa B (NF-B) signalling cascades, the main target of TLR4 activation. This, in turn results in the translocation and transcription of NF-B-driven cellular signals in immune cells, producing downstream synthesis and release of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-␣), interleukin-1␤ (IL-1␤), interleukin-6 (IL-6) and interleukin-8 (IL-8) [5] . Dynorphin 1-17 (DYN 1-17) is a 17-residue endogenous opioid peptide derived from prodynorphin precursors found in mammalian tissues. Our previous studies have demonstrated that DYN 1-17 undergoes biotransformation in rodent inflamed tissue, resulting in a unique set of opioid and non-opioid fragments [6] . and its N-terminal biotransformation fragments have been shown to be involved in the modulation of LPS-induced NF-B/p65 nuclear translocation and the subsequent release of IL-1␤ and TNF-␣ in THP-1 cell-derived macrophages through the kappa-opioid receptor (KOR) pathway [7] . In addition to the well-described analgesic effects, DYN 1-17 and its major biotransformation fragments have been shown to be involved in the regulation of cellular and humoral immune responses [8, 9] . Structurally related fragments of DYN [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] have been demonstrated to enhance the LPS-or interferon-gamma (IFN-␥)-stimulated tumouricidal effect in murine macrophages [10] , triggering the zymosan-mediated oxidative burst in the macrophage cell line J774 [11] . and suppression of the natural killer cells and antigen-specific cytolytic T-cell activity [12] upon engagement with the respective opioid receptors.
Evidence suggests that the immunomodulatory role of opioids in both innate and adaptive immunity [13] is due to the presence of classical opioid receptors on both the central immune cells (microglia and astrocytes) and peripheral immune cells (macrophages, lymphocytes and T cells) [14] . Nevertheless, nonopioid receptor sites have also been reported to be implicated in opioid-induced immunomodulation. For instance, morphine at micromolar concentrations was found to inhibit the LPS-induced interleukin-6 (IL-6) and TNF-␣ release associated with attenuation of NF-B activation in mouse peritoneal macrophages. This effect however was not reversed by naloxone, indicating the involvement of a non-opioid receptor mechanism [15] . Furthermore, inhibition of LPS-induced NF-B activation and subsequent IL-1␤ release following naloxone treatment in RAW264 cells was mediated by L-type calcium channels [16] . The enhancement of phagocytosis by DYN 1-17 in mouse peritoneal macrophages was reported to be dependent on intracellular calcium signalling [17] , whereas in another study, the inhibition of LPS-induced production of nitric oxide and TNF-␣ by DYN 1-8 was not blocked by the KOR antagonist norbinaltorphimine (nor-BNI), indicative of the involvement of non-opioid mechanisms in these inhibitory effects [18] .
Hutchinson et al. have identified TLR4 as one of the possible sites for non-opioid receptor mediated mechanisms by highlighting a non-stereoselective reversal of neuropathic pain by both enantiomers of the opioid antagonists, naloxone and naltrexone, through inhibition of LPS-induced TLR4 signalling [19] . Moreover, morphine non-stereoselectively triggered TLR4 signalling in glial cells and this effect was notably blocked by (+)-naltrexone, (+)-naloxone, and (−)-naloxone, which then shown to be novel TLR4 antagonists. Opioid-induced MD-2/TLR4 signalling was also observed in vivo using TLR4 knock-out mice [20] . Further in silico docking analysis of human MD-2 has identified that MD-2, a potential binding site for opioids in the TLR4/MD-2 complex, might implicate the TLR4 as signalling pathway. This finding has been subsequently confirmed by structural and functional studies [21] . Furthermore, in the absence of LPS, enantiomers of stereoisomeric opioids such as morphine and methadone still displayed significant TLR4 activation [20] .
Inflammation is activated by LPS binding TLR4, and identifying immune-modulatory roles of DYN fragments and underlying mechanisms in LPS-induced activation of pro-inflammation in peripheral immune cells is essential to better understand the role endogenous opioids play in pain and inflammation. In this study, we extend the findings from the previous DYN 1-17 biotransformation study by assessing the immunomodulatory effects of DYN 3-14 fragment, a fragment produced abundantly in the inflamed tissue homogenate, on LPS-induced NF-B/p65 nuclear translocation and downstream release of pro-inflammatory cytokines (IL-1␤ and TNF-␣) in differentiated THP-1 cells. Subsequently, HEK-Blue TM -hTLR4 cells were used to evaluate the involvement of TLR4 activation in mediating these effects.
Materials and methods

Peptide and reagents
DYN 3-14 was supplied by Mimotopes Pty. Ltd, Australia with purity greater than 95%. LPS from Escherichia coli, serotype O55:B5 was purchased from Enzo Life Sciences (Farmingdale, NY, USA), phorbol 12-myristate 13-acetate (PMA) was purchased from Adipogen (San Diego, CA, USA) and 4 ,6-diamidino-2-phenylindole (DAPI) was purchased from Cayman Chemical (MI, USA). Primary rabbit monoclonal anti-NF-B/p65 [E379] antibody (ab32536) and goat anti-rabbit IgG H&L (Alexa Fluor 555; ab150078) were provided by Abcam (Cambridge, MA, USA). The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent, dimethylsulfoxide (DMSO), N-(3, 5-bis-trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide (IMD-0354) and foetal bovine serum (FBS) were purchased from Sigma Aldrich (St Louis, MO, USA) whereas penicillin-streptomycin solution, Dulbecco's Modified Eagle's Medium (DMEM) and RPMI 1640 medium were supplied by Life Technologies (VIC, Australia). Normocin, HEK-Blue Selection and QUANTI-Blue TM solution were purchased from Invivogen (San Diego, CA, USA).
Cell cultures
THP-1 cells
The human monocytic THP-1 cells (ATCC No TIB-202) were maintained as described previously [22] . Briefly, THP-1 cells were grown in suspension in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 2 g/L D-glucose, 100 U/mL penicillin and 100 g/mL streptomycin in a humidified atmosphere of 5% CO 2 at 37 • C. THP-1 cells were stimulated with 50 nM PMA for 48 h to allow differentiation into a functional macrophage-like state. Cells were sub-cultured when 80-90% confluence was reached.
HEK-Blue TM hTLR4 cells
HEK-Blue TM hTLR4 cells comprised of stably transfected HEK-293 cells with human TLR4 receptor gene, MD2/CD14 co-receptor genes and a reporter plasmid expressing a secreted embryonic alkaline phosphatase (SEAP) containing NF-B response elements. Upon TLR4 stimulation with LPS, HEK-Blue TM -hTLR4 cells activate NF-B transcription factor and subsequently secrete SEAP. A similar protocol for maintaining HEK-Blue TM -hTLR4 cell line (Invivogen, CA, USA) was followed with slight modifications [23] . Briefly, the cells were routinely grown and maintained in DMEM supplemented with 10% heat-inactivated FBS, 2 mM l-glutamine, 4.5 g/L glucose, 1X HEK-Blue Selection, 100 g/mL normocin, 50 U/mL penicillin and 50 g/mL streptomycin at 37 • C in 5% CO 2 . Cells were sub-cultured when 80-90% confluence was reached.
NF-ÄB/p65 translocation assay
To measure the effects of DYN 3-14 on NF-B/p65 translocation, differentiated THP-1 cells (1.5 × 10 5 cells/mL) were seeded in 96-well black plates and stimulated with LPS (1 g/mL, previously optimised) in the presence of DYN 3-14 at two concentrations (10 nM and 1 M) for 24 h at 37 • C under 5% CO 2 . Non-stimulated cells received equivalent volume of the diluent (sterile ultrapure water), serving as the negative control. To check the functionality of the NF-B/p65 translocation assay, a synthetic, selective NF-B inhibitor, IMD-0354 (10 M in 0.1% DMSO) was used to treat both LPS-and non-stimulated cells for an hour under similar condi-tions. The corresponding DMSO concentration (0.1%) was prepared accordingly as a diluent control for IMD-0354.
Treated cells were fixed with freshly prepared cold formaldehyde (3.7%) for 15 min followed by incubation in blocking buffer (containing 5% normal goat serum and 0.3% Triton X-100) for an hour at room temperature. Primary anti-NF-B/p65 monoclonal antibody (1:400; Abcam, ab32536) was then added into each well and incubated overnight at 4 • C. Next, the cells were incubated with secondary Alexa Fluor ® 555 goat anti-rabbit IgG (H + L) polyclonal antibody (1:500; Abcam, ab150078) for 2 h followed by 4 ,6-diamidino-2-phenylindole (DAPI) staining (2 g/mL) for nucleic acid detection for 10 min at room temperature under subdued laboratory lighting. Cells were washed with PBS in triplicate between the incubations. Images of the experimental plates were acquired using the widefield ImageXpress ® Micro XLS automated high-content imaging system (Molecular Devices, CA, USA). Four fields of view (2000 pixel × 2000 pixel each) were captured from each well with a 10 × Plan Fluor (NA 0.3) objective. Acquired images were analysed using a customised Translocation-Enhanced application module built in the MetaXpress ® version 6.1 image analysis software (Molecular Devices, CA, USA). NF-B/p65 immunofluorescence derived from the images at the nuclear level, as identified by DAPI staining, was evaluated as positive DAPI overlapping pixels. The number of overlapping pixels in NF-B/p65 (green) images and DAPI (blue) images from each cellular nuclear area obtained from multiple images were determined and logged into an Excel spreadsheet.
Cell viability assay
The effect of DYN 3-14 on the viability of THP-1 cells was assessed using the colorimetric MTT assay. Cells (5 × 10 5 cells/mL) were seeded in 24-well culture plates and incubated with a low (10 nM) and high (1 M) concentration of DYN 3-14 for 24 h followed by incubation with the MTT reagent (2.5 mg/mL) for another 2 h at 37 • C. Cells incubated with culture medium alone served as the positive control for this assay. The formazan crystals were dissolved with DMSO and 100 L of each sample was transferred in duplicate into a 96-well plate. Wells containing DMSO only in equivalent volume were used as blank. The optical density of the produced intracellular formazan, proportional to the number of viable cells present, was read spectrophotometrically at 590 nm using iMark TM microplate absorbance reader (Bio-Rad Laboratories, CA, USA). The average viable cell value after blank absorbance subtraction was calculated as a fraction of the average value obtained from cells incubated with medium alone.
IL-1ˇ and TNF-˛ AlphaLISA immunoassay
Differentiated THP-1 cells (2 × 10 5 cells/mL) were seeded in 96-well plates and stimulated with 1 g/mL LPS [7] to release IL-1␤ and TNF-␣ in combination with DYN 3-14 at various concentrations as indicated in the figure at 37 • C under 5% CO 2 . The level of human IL-1␤ and TNF-␣ release was quantified using AlphaLISA kit (Perkin Elmer, VIC, Australia) according to the manufacturer's protocol. At the end of the 24 h treatment period with DYN 3-14, 1 L of standard or culture supernatant was added to a 384-well white microplate in duplicate followed by addition of 4 L/well of MIX solution. The MIX solution consists of 25 g/mL AlphaL-ISA anti-analyte acceptor beads and 2.5 nM biotinylated antibody anti-analyte were prepared in 1X AlphaLISA immunoassay buffer. The microplate was incubated for 60 min at 23 • C on an orbital shaker (Ratek Instruments, VIC, Australia) with gentle continuous agitation under subdued laboratory lighting. To detect the assay signal, 5 L streptavidin-coated donor beads solution (80 g/mL) were added into each well and the assay microplate was incubated for an additional 30 min at room temperature. The AlphaLISA signal was then read using an EnSpire ® Alpha 2390 plate reader equipped with AlphaScreen ® module (Perkin Elmer, VIC, Australia), where the bead complex was excited to 680 nm and the emission signals were collected at 615 nm. The unknown analyte concentration was determined using a variable slope regression analysis to fit the data points to a standard curve.
TLR4 signalling assay
To assess TLR4 signalling correlation with NF-B activation through SEAP production, HEK-Blue TM -hTLR4 cells (2 × 10 5 cells/mL) were seeded in each well of 96-well plates (200 L volume). The concentration-response curve for LPSinduced TLR4 activation was initially determined by stimulating the cells with 10 −13 -10 −6 M of LPS for 24 h at 37 • C. The efficacy of DYN 3-14 (10 M) LPS-RS (6.7 nM), a potent TLR4 inhibitor, on LPS concentration-response curve was determined under similar conditions. The molecular weight of LPS-RS was calculated to be 1497.8 Da. Using LPS submaximal concentration at 1 ng/mL, the potency of both compounds compared by constructing concentration-inhibitory response curves. The SEAP levels were determined with a colorimetric enzyme assay, QUANTI-Blue TM (Invivogen, CA, USA) according to the manufacturer's protocol and the optical density was measured at 655 nm wavelength using iMark TM microplate absorbance reader (Bio-Rad Laboratories, CA, USA).
Statistical analysis
All experiments were performed in triplicate and repeated in at least three independent experiments. Data are presented as mean ± standard error of the mean (SEM). GraphPad Prism ® 6.07
(GraphPad Software Inc, USA) was used for all data analysis. Multiple comparisons between groups were analysed using one-way ANOVA followed by Bonferroni post-hoc test. Non-linear regression was used to plot and analyze concentration-response curves and to obtain estimates for IC 50 . P values <0.05 were considered as statistically significant.
Results
DYN 3-14 inhibits NF-ÄB/p65 nuclear translocation in LPS-stimulated THP-1 cells
The LPS-induced NF-B/p65 nuclear translocation in THP-1 cell-derived macrophages was observed qualitatively upon immunolabelling of the cells with NF-B/p65 primary antibody. Representative images of non-stimulated cells are illustrated in the top panel of Fig. 1 (panel A, B and C) . In the absence of LPS, p65 subunit of NF-B (green) was observed predominantly in the cytoplasm (Fig. 1, panel B) . Further LPS stimulation resulted in a distinct nuclear labelling of NF-B/p65 in stimulated cells (Fig. 1, panel  E) , reflecting the translocation of cytosolic NF-B/p65 protein into the nuclei. Measurement of NF-B/p65 nuclear translocation index showed that LPS induced more than 50% of NF-B/p65 protein translocation into the nuclei compared to the non-stimulated cells (p < 0.05), confirming that LPS stimulation resulted in NF-B/p65 translocation to the nucleus in PMA-differentiated THP-1 cells. The modulatory effects of DYN 3-14 at 10 nM and 1 M on were then measured in both non-stimulated and LPS-stimulated THP-1 cells. Co-incubation of LPS with DYN 3-14 at both low and high concentrations significantly inhibited NF-B/p65 nuclear translocation when compared to the LPS control group (Fig. 2) . DYN 3-14 at 10 nM displayed the greatest inhibitory effect on LPS-induced NF-B/p65 nuclear translocation (approximately 33%), comparable to IMD-0354, a potent NF-B inhibitor. DYN 3-14 (at 10 nM and 1 M) and IMD-0354 had no significant effect on the basal level of NF-B/p65 nuclear translocation in the absence of LPS stimulation (LPS, 100.00 ± 0.60; DYN 3-14 at 10 nM, 100.07 ± 1.53; at 1 M, 100.47 ± 1.56; IMD-0354, 100.63 ± 1.63; p > 0.05).
Effects of DYN 3-14 on THP-1 cell viability
Results for cell viability (MTT assay) revealed that incubation with DYN 3-14 did not affect cell viability in LPS-stimulated, differentiated THP-1 cells at the concentrations tested (LPS, 100.00 ± 1.07; DYN 3-14 at 10 nM, 112.30 ± 0.99; at 1 M, 109.40 ± 7.43; p > 0.05).
DYN 3-14 inhibits LPS-induced IL-1ˇ and augments TNF-r elease in differentiated THP-1 cells
To determine the effect of DYN 3-14 on LPS-induced cytokine production, the amount of IL-1␤ and TNF-␣ released from LPS stimulated THP-1 cells was measured. Differentiated THP-1 cells were co-incubated with 1 g/mL of LPS in the presence of the DYN 3-14 at concentrations of 10 −17 to 10 −7 M. LPS alone significantly induced the release of IL-1␤ and TNF-␣ levels in differentiated THP-1 cells after 24 h when compared to the non-stimulated cells [IL-1␤: LPS-stimulated, 100.00 ± 1.74; non-stimulated, (3.64 ± 2.91; p < 0.05) and TNF-␣: LPS-stimulated, 100.00 ± 3.29; non-stimulated, (2.25 ± 0.44; p < 0.05)]. In the presence of DYN 3-14, the induction of IL-1␤ release by LPS was significantly inhibited at 10 −17 to 10 −11 M in a concentrationindependent manner (Fig. 3A, p < 0.05) . In contrast, DYN 3-14 at concentrations of 10 −11 to 10 −7 M further augmented the LPSinduced TNF-␣ levels in differentiated THP-1 cells (Fig. 3B, p < 0.05) . The other concentrations of DYN 3-14, however did not display any significant modulation on IL-1␤ or TNF-␣ release following LPS stimulation. Treatment with DYN 3-14 alone without LPS showed no effect on both cytokine levels (data not shown).
Effects of DYN 3-14 on the LPS-induced TLR4 signalling in HEK-Blue TM hTLR4 cells
TLR4 selectively recognizes LPS, leading to downstream inflammatory-related intracellular responses including translocation of NF-B and release of pro-inflammatory cytokines [24] . To investigate a specific interaction of DYN 3-14 on TLR4 activity following LPS stimulation, HEK-Blue TM cells that stably overexpressed TLR4 were employed. The concentration-dependent effects of LPS at TLR4 reached a maximal response at 10 −6 g/mL of LPS (Fig. 4, solid line) , with an EC 50 of 0.46 ± 1.05 ng/mL. The TLR4 antagonistic effects of DYN 3-14 (10 M) and LPS-RS (6.7 nM) were assessed against concentration-response curves for LPS. DYN 3-14 shifted the LPS concentration-response curve to the right with a higher EC 50 value of 0.78 ± 1.08 ng/mL (Fig. 4, dashed line) . LPS-RS resulted in a greater shift to the right with an EC 50 value of 1.42 ± 1.07 ng/mL (Fig. 4, dotted line) . The F-test with a value of 74.82 rejected the null hypothesis, indicating that the log EC 50 values for each slope are different from LPS. Both DYN 3-14 and LPS-RS, achieved similar maximal inhibition of LPS induced TLR4 activation at 10 −6 g/mL, indicating that are both full antagonists for the TLR4 receptor complex. To investigate the concentration dependent effects of the antagonists, a submaximal concentration of LPS was utilized (1 ng/mL). DYN 3-14 ( inhibition of LPS-induced TLR4 activation, however LPS was fully inhibited for both DYN 3-14 and LPS-RS. DYN 3-14 alone had no effect on TLR4 signalling in the absence of LPS (data not shown).
Discussion
This study investigates the modulatory effect of the non-opioid DYN 1-17 fragment, DYN 3-14, on NF-B activation and subsequent downstream release of pro-inflammatory cytokines. DYN 1-17 is released by leukocytes in inflamed tissue and plays an important role in regulating inflammatory pain [25] . Biotransformation resulting in the removal of the amino-terminal tyrosine (Tyr) residue in opioid peptides yields fragments that are structurally "non-opioid" in nature with very low affinity for opioid receptors [26] . The immunoregulation observed may be facilitated by a range of opioid and non-opioid fragments, produced following biotransformation of DYN 1-17 at the site of inflammation [6] . Outside of traditional opioid receptor-mediated effects, evidence of non-opioid receptors roles for opioid peptides include action at melanocortin receptors [27, 28] , bradykinin receptors [29] , Nmethyl-D-aspartate (NMDA) receptor complex [30] and recently the TLR4 [20] , therefore the overarching effects of biotransformed opioid peptides may involve a number of possible mechanisms. It is likely that DYN 3-14, the most abundant fragment of DYN 1-17 produced in inflamed tissue, modulates inflammatory responses through one of these mechanisms. TMhTLR4 reporter cell lines were stimulated with LPS alone (concentrations ranging from 10 −12 to 10 −6 g/mL), with combination of LPS and DYN 3-14 (10 M) or with combination of LPS and LPS-RS (6.7 nM) for 24 h. The percentage of maximal response of TLR4 activation in each treatment group was normalized and expressed relative to LPS alone-stimulated control group. Mean ± SEM is shown, n = 7 independent experiments, EC50 was assessed using non-linear regression. IL-1␤ and TNF-␣ were released in response to LPS treatment, consistent with the previously reported cytokine expression profile in differentiated THP-1 cells following LPS stimulation [31] . Herein, we demonstrated that DYN 3-14 modulated IL-1␤ and TNF-␣ differentially. While the release of IL-1␤ was reduced following incubation with DYN 3-14 (10 −11 to 10 −17 M), DYN 3-14 further elevated TNF-␣ release induced by LPS in differentiated THP-1 cells. An earlier study has shown that DYN fragments at low concentrations (10 −16 to 10 −12 M) significantly modulated LPS-induced TNF-␣ and nitric oxide by inhibiting the production of these inflammatory mediators in mouse primary mixed glia cultures, implicating the involvement of a novel ultrahigh-affinity receptor in mediating these inhibitory effects [18] . Supporting this notion, significant opioid peptide actions on immune cells at ultralow concentrations also have been reported in a number of experimental studies in a range of cell types [32] [33] [34] .
The differential effects seen on cytokine release in this study are consistent with evidence from a previous study, showing that ␤-endorphin and naltrindole elevated IL-1␤ production and suppressed TNF-␣ level in LPS-stimulated peripheral blood monocytes [35] . The differential secretion of TNF-␣ and IL-1␤ following LPS induction in isolated mouse macrophages further describes the complexity of cytokine modulation by immune cells [36] . LPSinduced TNF-␣ production is regulated by a number of intracellular signal transduction pathways, including the activation of mitogenactivated protein kinase (MAPK) family [37] . LPS is able to induce extracellular-signal-regulated kinase-1 (ERK1) and ERK2, c-Jun Nterminal kinases (JNKs) and p38, which results in increased TNF-␣ translation [38, 39] . Activation of ERK also leads to transcription of c-Fos and AP-1 formation [40] . Interestingly, several AP-1 binding regions have been identified on the TNF-␣ promoter, thus TNF-␣ secretion is also elicited through an AP-1 transcription factor [37, 41] . It is possible that, DYN 3-14 promotes ERK-dependent expression of AP-1 proteins, resulting in elevation of TNF-␣ level in differentiated THP-1 cells, this however requires further investigation to confirm.
Differential effects of DYN 3-14 on both IL-1␤ and TNF-␣ release suggests that this peptide is a biased antagonist at TLR4. Biased ligand refers to ligands that are able to stabilize multiple unique receptor confirmations, resulting in collateral activation of multiple intracellular pathways produced by interaction of different cellular coupling proteins [51] . Another example of a biased ligand is the ␤-blocker propranolol. It is an ERK activator and at the same time inversely agonizes G s alpha subunit (G s␣ )-mediated cAMP formation, denoting that some ligands can be agonists for some pathways and antagonists for others [52] . The concept of biased ligand represents a novel approach for the development of more effective and better tolerated drugs as differential effects on cellular inflammatory processes may have implication clinically.
In this study, the increased nuclear labelling of NF-B/p65 (green) following LPS stimulation reflects the translocation of cytosolic NF-B/p65 into the nuclei. Under resting conditions, inactive NF-B is bound to its inhibitory protein, the IB protein in the cytoplasm. Activation of the IKK complex by LPS phosphorylates the IB protein, releasing the NF-B complex followed by translocation into the nucleus [42] . Engagement of the NF-B complex with DNA promoter regions in the nucleus then leads to transcription and expression of various inflammatory mediators including cytokines [43] . DYN 3-14 was shown in this study to attenuate NF-B/p65 nuclear translocation in LPS-stimulated THP-1 cells, comparable to that of the selective IKB␣ phosphorylation inhibitor, IMD-0354. Moreover, DYN 3-14 had no effect on the viability of THP-1 cells, excluding non-specific cytotoxicity as a possible explanation for the NF-B/p65 inhibition. NF-B has been implicated in the regulation of a plethora of genes involved in inflammation; inhibition of NF-B/p65 nuclear translocation will eventually terminate the transcription of pro-inflammatory genes in the activated macrophages, thereby limiting the severity of an inflammatory response [44] .
The activation of NF-B by LPS is principally mediated through the TLR4 receptor [5, 45] . A number of studies have reported the involvement of numerous opioids in modulation of TLR4 signalling pathway [46] [47] [48] . For this reason, HEK-Blue TM -hTLR4 cells were used to elucidate the mechanism underlying the modulation nonopioid DYN fragments, as these cells overexpress TLR4 receptors. LPS from Escherichia coli O111:B4 was used to stimulate the inflammatory response and this compound specifically activates TLR4 selectively [49] , excluding the involvement of other TLRs. This study showed that DYN 3-14 blocks LPS-induced TLR4 signalling in the HEK-Blue TM -hTLR4 cells, which provides a mechanistic insight into the inhibition of NF-B/p65 translocation seen with the DYN 3-14 in the differentiated THP-1 cells. The selectivity of the modulatory effect of DYN 3-14 at TLR other than TLR4 has not been explored. However, other biotransformed fragments including a range of non N-terminal dynorphin-related peptides such as DYN 2-17, DYN 6-12, DYN 7-17 and DYN 3-6 have been investigated utilizing the TLR4 overexpressed HEK cells but none of these fragments modulated TLR4 signalling, providing some insights into the selective nature of DYN 3-14 action (data not shown).
LPS-RS, derived from Rhodobacter sphaeroides is a potent competitive inhibitor of LPS at TLR4 in both human and murine cells [50] . LPS in the presence of DYN 3-14 or LPS-RS revealed that both compounds are capable of complete inhibition of LPS effects on TLR4. LPS-RS, however, exhibits a higher potency in comparison to DYN 3-14 as an antagonist of LPS-induced TLR4 signalling. In congruence with the lower potency exhibited by DYN 3-14, this peptide was produced abundantly following biotransformation of DYN 1-17 in rodent inflamed tissue homogenate [6] . Furthermore, DYN 3-14 does not undergo rapid degradation (93.40% remaining after 1 h, data not shown) upon incubation with THP-1 cells, suggesting that high local concentrations are present in the inflammatory milieu. In addition, DYN 3-14 at higher concentrations (10 M) inhibited LPS-induced TLR4 signalling in overexpressing TLR4 cells. Taken together, it can be postulated that DYN 3-14 may be produced in high quantities at localized sites of inflammation resulting in anti-inflammatory effects.
In conclusion, this study provides a mechanistic insight into biotransformed endogenous opioid peptide of DYN 1-17 involvement in immunomodulation and highlights a possible new avenue for therapeutic intervention. Consistent with the abundant local accumulation of DYN 3-14 following biotransformation of DYN 1-17 in rodent inflamed tissue [6] , this study has described a potential role for DYN 3-14 as an endogenous immune modulator in the tissue through modulation of pro-inflammatory cytokine release and the action upon TLR4-mediated NF-B/p65 pathways.
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